INAQOVI Film-coated tablet Ref.[51639] Active ingredients: Cedazuridine Decitabine Decitabine and Cedazuridine

Source: European Medicines Agency (EU)  Revision Year: 2023  Publisher: Otsuka Pharmaceutical Netherlands B.V., Herikerbergweg 292, 1101 CT Amsterdam, Netherlands

4.3. Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

Breast-feeding (see section 4.6).

4.4. Special warnings and precautions for use

Myelosuppression

Fatal and serious myelosuppression can occur with treatment (see section 4.8).

Complete blood cell counts must be obtained prior to the initiation of treatment, prior to each cycle, and as clinically indicated to monitor response and toxicity. Growth factors and anti-infective therapies must be administered for treatment or prophylaxis as appropriate. The next cycle must be delayed and resumed at the same or reduced dose as recommended (see sections 4.2 and 4.8). Patients must be monitored for signs and symptoms of infection and treated promptly.

Neutropaenia

Supportive treatments include, administration of prophylactic antibiotics and/or growth factor support (e.g., G-CSF) for neutropaenia according to institutional guidelines. For situations where administration must be delayed, see section 4.2.

Respiratory, thoracic and mediastinal disorders

Cases of interstitial lung disease (ILD) (including pulmonary infiltrates, organising pneumonia and pulmonary fibrosis) without signs of infectious aetiology have been reported in patients receiving intravenous decitabine. Patients with an acute onset or unexplained worsening of pulmonary symptoms must be carefully assessed to exclude ILD. If ILD is confirmed, appropriate treatment must be initiated (see section 4.8).

Hepatic impairment

Use in patients with hepatic impairment has not been established. Caution must be exercised in the administration of medicinal product to patients with hepatic impairment and in patients who develop signs or symptoms of hepatic impairment. Liver function tests must be performed prior to the initiation of therapy, prior to each treatment cycle, and as clinically indicated (see sections 4.2 and 5.2).

Renal impairment

Use in patients with severe renal impairment has not been studied. Caution must be exercised in the administration of the medicinal product to patients with severe renal impairment (CrCl <30 mL/min). Renal function tests must be performed prior to the initiation of therapy, prior to each treatment cycle, and as clinically indicated (see sections 4.2 and 5.2).

Cardiac disease

Patients with a history of severe congestive heart failure or clinically unstable cardiac disease were excluded from clinical studies and therefore, the safety and efficacy of the medicinal product in these patients has not been established. Cases of cardiomyopathy with cardiac decompensation, in some cases reversible after treatment discontinuation, dose reduction or corrective treatment, have been reported in the postmarketing setting with intravenous decitabine (see section 4.8). Patients, especially those with a history of cardiac disease, must be monitored for signs and symptoms of heart failure.

Differentiation syndrome

Cases of differentiation syndrome (also known as retinoic acid syndrome) have been reported during the post-marketing period with intravenous decitabine (see section 4.8). Differentiation syndrome may be fatal (see section 4.8). Treatment with high-dose intravenous corticosteroids and haemodynamic monitoring must be considered at first onset of symptoms or signs suggestive of differentiation syndrome. Treatment must be temporarily discontinued until symptoms resolve, and if resumed, caution is advised.

Administration of antiemetics

Nausea and vomiting may occur during treatment. Administration of standard antiemetic therapy prior to each dose should be considered to minimise nausea and vomiting.

Excipients

Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucosegalactose malabsorption should not take this medicinal product.

This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

4.5. Interaction with other medicinal products and other forms of interaction

Effect of other medicinal products on Inaqovi

Decitabine and cedazuridine are not substrates or inhibitors for cytochrome P450 (CYP450); thus interactions with CYP inhibitors or inducers are not expected.

Cytidine deaminase inhibitors

Because decitabine is a substrate for the cytidine deaminase (CDA) enzyme, which metabolises decitabine resulting in an inactive deaminated form, other medicinal products inhibiting CDA should be avoided, as co-administration may result in increased decitabine exposure.

Effect of Inaqovi on other medicinal products

Medicinal products metabolised by cytidine deaminase

Cedazuridine is an inhibitor of CDA and thereby increases the exposure of decitabine following oral administration. Concomitant administration of Inaqovi with medicinal products metabolised by CDA (i.e., cytarabine, gemcitabine, azacitidine) may result in increased systemic exposure with a potential for increased toxicity of these medicinal products. Co-administration of Inaqovi with medicinal products metabolised primarily by CDA should be avoided.

Food

Overall decitabine exposure has been shown to be reduced when decitabine is administered with a highfat, high-calorie meal (see section 4.2).

4.6. Fertility, pregnancy and lactation

Women of childbearing potential/Contraception in men and women

Due to the genotoxic potential of decitabine (see section 5.3), women of childbearing potential must use effective contraceptive measures and avoid becoming pregnant while being treated with Inaqovi and for 6 months following completion of treatment. Men should use effective contraceptive measures and be advised to not father a child while receiving Inaqovi, and for 3 months following completion of treatment (see section 5.3).

The use of decitabine and cedazuridine with hormonal contraceptives has not been studied.

Pregnancy

There are no or a limited amount of human data from the use of decitabine and cedazuridine in pregnant women.

Based on the results of embryo-foetal toxicity studies conducted in animals (see section 5.3), Inaqovi may harm the foetus when administered to pregnant women.

Studies in animals have shown reproductive toxicity (see section 5.3).

Inaqovi is not recommended during pregnancy and in women of childbearing potential not using effective contraception. A pregnancy test should be performed on all women of childbearing potential before treatment is started. If Inaqovi is used during pregnancy, or if a patient becomes pregnant while receiving this medicinal product, the patient should be apprised of the potential hazard to the foetus.

Breast-feeding

It is unknown whether decitabine, cedazuridine, or their metabolites are excreted in breast milk.

A risk to the newborns/infants cannot be excluded.

Inaqovi is contraindicated during breast-feeding (see section 4.3).

Fertility

No human data on the effect of decitabine and cedazuridine on fertility are available. Ovarian and testicular toxicity, including mutagenicity, has been observed in repeat-dose toxicity studies in mice. Because of the possibility of infertility as a consequence of therapy, men should seek advice on conservation of sperm and female patients of childbearing potential should seek consultation regarding oocyte cryopreservation prior to initiating treatment. Before starting treatment or planning pregnancy, consider the above guidance (see section 5.3).

4.7. Effects on ability to drive and use machines

Inaqovi has moderate influence on the ability to drive and use machines. Patients should be advised that they may experience undesirable effects, such as anaemia during treatment. Therefore, caution should be observed when driving a car or operating machinery.

4.8. Undesirable effects

Summary of safety profile

The safety of Inaqovi was evaluated in one Phase 3 study (ASTX727-02-EU) where 80 AML patients received the medicinal product. The overall safety profile for Inaqovi is described below and also reflects the known safety profile of intravenous decitabine.

Among the 80 patients who received treatment, the most common adverse drug reaction (≥20%) including Grade ≥ 3 was thrombocytopaenia.

The most common serious adverse reactions (≥20%) were febrile neutropaenia and pneumonia.

Deaths while on treatment occurred in 24% of patients. The most frequent adverse reactions resulting in death included pneumonia (8%), sepsis (3%) and central nervous system haemorrhage in the setting of thrombocytopaenia (3%).

Permanent discontinuation occurred in 14% of patients while on treatment. The most frequent adverse reaction resulting in permanent discontinuation was pneumonia (5%).

Treatment interruption and dose reductions occurred in 48% of patients. The most frequent adverse reaction resulting in treatment interruption and dose reduction was myelosuppression occurring in 19% of patients (n=15) (neutropaenia [13%, n=10], febrile neutropaenia [5%, n=4], and thrombocytopaenia [3%, n=2]). The adverse reaction pneumonia led to treatment interruption and dose reduction in 5% of patients.

Tabulated list of adverse reactions

The safety evaluation of adverse reactions is largely based on experience with Dacogen in patients with AML. The safety of Inaqovi in adult patients was evaluated in a safety population that included AML patients from one Phase 3 study (ASTX727-02-EU, N=80).

Among the 80 patients who received Inaqovi, 38% were exposed for 6 months or longer and 6% were exposed for greater than 1 year.

Table 2 lists adverse drug reactions associated with Inaqovi (N=80), or that have been associated with intravenous decitabine, according to system organ class (SOC) in MedDRA. Within each SOC, the adverse drug reactions are ranked by frequency and then presented in order of decreasing seriousness. The corresponding frequency category for each adverse drug reaction is defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare (≥1/10 000 to <1/1 000); very rare (<1/10 000); not known (cannot be estimated from available data).

Table 2. Adverse drug reactions observed with Inaqovi or with intravenous decitabine therapy in AML patients:

MedDRA SOC MedDRA Terma AML (N=80)
All CTCAE Grades CTCAE Grade 3-4
% Frequency% Frequency
Infections and
infestations
All other infections
(viral, bacterial,
fungal)b
50.0 Very common 25.0 Very common
Pneumoniac 23.8 Very common 18.8Very common
Sepsisd 10.0 Very common 6.3 Common
Urinary tract
infectione
17.5 Very common 2.5 Common
Sinusitis (including
fungalf and
bacterialg)
2.5 Common 2.5 Common
Blood and
lymphatic system
disorders
Leukopeniah 81.3 Very common 67.5 Very common
Thrombocytopaeniah,i 73.8 Very common 67.5 Very common
Anaemiah 67.5 Very common 60.0 Very common
Neutropaeniah,j 41.8 Very common 41.8 Very common
Febrile neutropaenia 28.8 Very common 26.3 Very common
Pancytopaeniak Not known Uncommonk Not known Uncommonk
Neoplasms benign,
malignant and
unspecified
(including cysts
and polyps)
Differentiation
syndromel
Not known Not known Not knownNot known
Metabolism and
nutrition
disorders
Hyperglycaemiah,m 61.1 Very common4.2Common
Nervous system
disorders
Headachen 2.5 Common Not knownCommonn
Cardiac disorders Cardiomyopathy^o^ Not known Uncommon Not known Uncommon
Respiratory,
thoracic and
mediastinal
disorders
Epistaxisn 6.3 Common Not known Commonn
Interstitial lung
diseasel
Not known Not known Not known Not known
Gastrointestinal
disorders
Stomatitisp 10.0 Very common 1.3 Common
Nauseaq 21.3 Very common Not known Uncommonq
Diarrhoear 13.8 Very common Not known Commonr
Vomitingr 12.5 Very common Not known Commonr
Neutropaenic
colitis^s^
1.3 Common 1.3 Common
Hepatobiliary
disorders
Aspartate
aminotransferase
increasedh,t
30.6 Very common 2.8Common
Alanine
aminotransferase
increasedh,u
28.8 Very common 2.7Common
Alkaline
phosphatase
increasedh,v
43.7 Very common 0Not
applicable
Bilirubin
increasedh,w,q
23.3 Very common Not known Uncommonf
Skin and
subcutaneous
tissue disorders
Acute febrile
neutrophilic
dermatosis (Sweet’s
syndrome)x
Not known Uncommonx Not
applicabley
Not
applicabley
General disorders
and administration
site conditions
Pyrexiaz 23.8 Very common 1.3Common

a The corresponding frequency category for each adverse drug reaction is based on the CIOMS III convention
b Grouped terms include anal abscess, anorectal infection, bacteraemia, cellulitis, cellulitis staphylococcal, corona virus infection, coronavirus test positive, enterococcal bacteraemia, enterocolitis viral, erythema, escherichia bacteraemia, folliculitis, furuncle, gingival swelling, herpes virus infection, infection, klebsiella bacteraemia, nasal congestion, nasopharyngitis, oral candidiasis, oral herpes, oropharyngeal candidiasis, otitis externa, periodontitis, pharyngitis, polyserositis, pseudomonal bacteraemia, staphylococcal bacteraemia, staphylococcal infection, streptococcal bacteraemia, respiratory tract infection, skin infection, tooth abscess, tooth infection, upper respiratory tract infection, varicella zoster virus infection
c Grouped terms include bronchitis, pneumonia
d Grouped terms include sepsis, septic shock, systemic candidiasis, urosepsis
e Grouped terms include bacteriuria, cystitis, dysuria, escherichia urinary tract infection, urinary tract infection, urinary tract infection enterococcal
f Grouped terms include sinusitis aspergillus, sinusitis fungal
g Sinusitis bacterial was not observed in the clinical trial with Inaqovi, however sinusitis (organism not specified) was observed in clinical trials with IV decitabine at a frequency of common (3%, 1%)
h Based on laboratory values
i Thrombocytopaenia may lead to bleeding and haemorrhagic reactions that may be fatal
j Neutrophils decreased (n=79)
k Pancytopaenia, including fatal events, was not observed in the clinical trial with Inaqovi, however it was observed in clinical trials with IV decitabine at a frequency of uncommon (<1%)
l Differentiation syndrome and interstitial lung disease were not observed in the clinical trial with Inaqovi, however they were observed in post-market setting with the use of IV decitabine
m Hyperglycemia (n=72)
n Headache and epistaxis Grade 3-4, were not observed in the clinical trial with Inaqovi, however they were observed in clinical trials with IV decitabine at a frequency of common (1% and 2%)
° Cardiomyopathy was not observed in the clinical trial with Inaqovi, however it was observed in clinical trials with IV decitabine at a frequency of uncommon (<1%)
p Grouped terms include aphthous ulcer, glossitis, oral discomfort, oropharyngeal discomfort, oropharyngeal pain, stomatitis, tongue ulceration, toothache q Nausea and bilirubin increased, Grade 3-4, were not observed in the clinical trial with Inaqovi, however it was
observed in clinical trials with IV decitabine at a frequency of uncommon (<1%)
r Diarrhoea and vomiting, Grade 3-4, were not observed in the clinical trial with Inaqovi, however they were observed in clinical trials with IV decitabine at a frequency of common (2% and 1%)
s Caecitis (including fatal events) was not observed in the clinical trial with Inaqovi, however they were observed in post-market setting with the use of IV decitabine
t Aspartate aminotransferase increased (n=72) u Alanine aminotransferase increased (n=73)
v Alkaline phosphatase increased (n=71)
w Bilirubin increased (n=73)
x Acute febrile neutrophilic dermatosis was not observed in the clinical trial with Inaqovi, however it was observed
in clinical trials with IV decitabine (all Grades) at a frequency of uncommon (<1%)
y Not applicable (Grade 3-4): Adverse drug reaction has not been observed with either Inaqovi or IV decitabine in both clinical trials and post-market
z Grouped terms include chills and pyrexia
CTCAE = Common Terminology Criteria for Adverse Events

Description of selected adverse reactions

Haematologic adverse drug reactions

The most commonly reported haematologic adverse drug reactions associated with treatment included leukopaenia, thrombocytopaenia, anaemia, neutropaenia and febrile neutropaenia. These adverse drug reactions are manifestations of myelosuppression and may present as pancytopenia.

Serious bleeding-related adverse drug reactions, such as gastrointestinal haemorrhage and cerebral haemorrhage in the context of severe thrombocytopaenia, were reported in patients receiving treatment. Bleeding may also occur with the eyes, skin, and mucous membranes (mouth and anorectal).

Haematological adverse drug reactions must be managed by routine monitoring of CBCs and early administration of supportive treatments as required. Supportive treatments include administration of prophylactic antibiotics and/or growth factor support (e.g., G-CSF) for neutropaenia and transfusions for anaemia or thrombocytopaenia according to institutional guidelines. For situations where treatment must be delayed, see section 4.2.

Infections and infestations adverse drug reactions

Serious infection-related adverse drug reactions, with potentially fatal outcome, such as septic shock, sepsis, pneumonia, and other infections (viral, bacterial and fungal) were reported in patients receiving treatment.

Gastrointestinal disorders

Occurrences of enterocolitis, including neutropaenic colitis, have been reported during treatment. Enterocolitis may lead to septic complications and may be associated with fatal outcome.

Respiratory, thoracic and mediastinal disorders

Cases of interstitial lung disease (including pulmonary infiltrates, organising pneumonia and pulmonary fibrosis) without signs of infectious aetiology have been reported in patients receiving intravenous decitabine.

Differentiation syndrome

Cases of differentiation syndrome (also known as retinoic acid syndrome) have been reported in patients receiving intravenous decitabine. Differentiation syndrome may be fatal and symptoms and clinical findings include respiratory distress, pulmonary infiltrates, fever, rash, pulmonary oedema, peripheral oedema, rapid weight gain, pleural effusions, pericardial effusions, hypotension and renal dysfunction. Differentiation syndrome may occur with or without concomitant leucocytosis. Capillary leak syndrome and coagulopathy can also occur (see section 4.4).

Other special populations

Elderly

Of the 80 patients in clinical studies who received Inaqovi, 39% were younger than 75 years, and 61% were 75 years and older. No overall differences in safety or effectiveness were observed between patients aged 75 years and older and younger patients.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

6.2. Incompatibilities

Not applicable.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.